% Susceptible 2016
Click Here for Printable viewOx | ||||||||||||||||||||||||||
- |
0 |
0 |
- |
+ |
95 |
0 |
0 |
81 |
87 |
+ |
97 |
99 |
+ |
98 |
98 |
88 |
88 |
97 |
100 |
- |
+ |
- |
- |
96& |
||
- |
65 |
70 |
- |
+ |
99 |
93 |
95 |
97 |
97 |
98 |
89 |
89 |
+ |
95 |
95 |
98 |
83 |
100 |
100 |
- |
- |
+ |
- |
- |
99& |
|
- |
0 |
0 |
- |
+ |
90 |
0 |
0 |
73 |
85 |
+ |
94 |
98 |
+ |
96 |
96 |
85 |
89 |
97 |
100 |
- |
- |
+ |
- |
- |
31& |
|
100 |
100 |
+ |
- |
+ |
+ |
- |
- |
- |
- |
- |
77 |
81 |
+ |
79S |
S |
- |
- |
+ |
+/- |
- |
- |
24 |
- |
99 |
99& |
|
66 |
66 |
- |
+/- |
+/- |
- |
- |
- |
- |
- |
24 |
29 |
+/- |
91S |
- |
- |
- |
+/- |
- |
- |
- |
38 |
- |
56 |
50& |
||
- |
+/- |
+ |
- |
+/- |
+ |
+ |
+ |
+ |
+ |
+ |
+ |
+ |
+ |
+ |
+ |
+/- |
+ |
+ |
+/- |
+ |
+ |
- |
- |
& |
||
- |
0 |
90 |
- |
+ |
99 |
96 |
94 |
98 |
98 |
98 |
97 |
99 |
+ |
98 |
98 |
98 |
93 |
100 |
100 |
- |
- |
+ |
- |
- |
57& |
|
- |
80 |
91 |
- |
+ |
100 |
91 |
97 |
98 |
99 |
100 |
74 |
76 |
+ |
86 |
91 |
98 |
76 |
+ |
100 |
-* |
-* |
0 |
-* |
-* |
0 |
|
- |
- |
- |
- |
+ |
99 |
- |
- |
- |
96 |
96 |
87 |
85 |
+ |
81 |
99 |
85 |
- |
93 |
99 |
- |
- |
- |
- |
- |
- |
|
- |
0 |
0 |
- |
+ |
96 |
0 |
0 |
94 |
96 |
100 |
95 |
98 |
+ |
99 |
97 |
96 |
97 |
99 |
100 |
- |
- |
- |
- |
- |
0 |
|
0 |
0 |
0 |
0 |
- |
- |
0 |
- |
0 |
- |
- |
19 |
21 |
81 |
- |
- |
- |
98 |
- |
- |
8 |
- |
95 |
73 |
100 |
96& |
|
0 |
- |
100 |
100 |
- |
+ |
100 |
+ |
100 |
+/- |
+ |
80 |
81 |
97 |
+ |
+ |
- |
100 |
+ |
+ |
69 |
+ |
96 |
89 |
100 |
99& |
|
0 |
0 |
48 |
48 |
+/- |
+-* |
+/- |
+/- |
48 |
+/- |
+/- |
56 |
57 |
73 |
89 |
+/- |
- |
54 |
+-* |
+-* |
19 |
+-* |
85 |
46 |
100 |
99& |
|
92# |
+ |
+ |
+ |
+ |
+ |
+ |
97 |
99# |
+/- |
99# |
+/- |
100 |
+ |
- |
- |
- |
89 |
+ |
97 |
86 |
86 |
93 |
92 |
100 |
& |
|
92 |
94 |
+ |
+- |
+ |
+ |
+ |
+ |
98 |
+/- |
98 |
+-* |
91 |
+ |
-* |
-* |
-* |
+ |
+ |
95 |
62 |
65 |
78 |
88 |
100 |
& |
|
100 |
100 |
+ |
+ |
+ |
+ |
100 |
+ |
100 |
+ |
+ |
+/- |
100 |
+ |
- |
- |
- |
- |
+ |
+ |
55 |
+ |
- |
67 |
100 |
& |
Numeric data represent local susceptibility data.
(+) = usually effective or >60% susceptible; (+/-) = clinical trials lacking or 30-60% susceptible; (-) = not effective clinically or <30% susceptible - Adapted with permission from The Sanford Guide to Antimicrobial Therapy
(*) Local (non-Sanford Guide) opinion
(S) = synergistic with penicillin/ampicillin
(&) nitrofurantoin only useful for lower tract urinary tract infections
(#) meningitis criteria
Pen(penicillin), Amp(ampicillin), Uns(Unasyn/Augmentin), Ox(Oxacillin/Nafcillin), Pip(piperacillin), P/T(piperacillin/tazobactam), Cfz(cefazolin), Cfr(cefuroxime), Cft(ceftriaxone), Ctz(Ceftazidime), Cfp(Cefepime), Cip(ciprofloxacin), Lev(levofloxacin), Mox(moxifloxacin), Gen(gentamicin), Tob(tobramycin), Azt(aztreonam), T/S(trimethoprim/sulfamethoxazole), Imp(imipenem), Mer(meropenem), Ery(erythromycin), Azi(azithromycin), Dox(doxycycline), Cln(Clindamycin), Van(Vancomycin), Ntf(nitrofurantoin)
(+) = usually effective or >60% susceptible; (+/-) = clinical trials lacking or 30-60% susceptible; (-) = not effective clinically or <30% susceptible - Adapted with permission from The Sanford Guide to Antimicrobial Therapy
(*) Local (non-Sanford Guide) opinion
(S) = synergistic with penicillin/ampicillin
(&) nitrofurantoin only useful for lower tract urinary tract infections
(#) meningitis criteria
Pen(penicillin), Amp(ampicillin), Uns(Unasyn/Augmentin), Ox(Oxacillin/Nafcillin), Pip(piperacillin), P/T(piperacillin/tazobactam), Cfz(cefazolin), Cfr(cefuroxime), Cft(ceftriaxone), Ctz(Ceftazidime), Cfp(Cefepime), Cip(ciprofloxacin), Lev(levofloxacin), Mox(moxifloxacin), Gen(gentamicin), Tob(tobramycin), Azt(aztreonam), T/S(trimethoprim/sulfamethoxazole), Imp(imipenem), Mer(meropenem), Ery(erythromycin), Azi(azithromycin), Dox(doxycycline), Cln(Clindamycin), Van(Vancomycin), Ntf(nitrofurantoin)